Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To US$100 Million 12
Private Equity 14
Mesoblast Raises USD10 Million in Financing 14
Partnerships 16
Mesoblast Enters into Partnership with Tasly Pharma 16
Mesoblast Enters into Agreement with Cartherics 17
Mesoblast Enters into Agreement with Mallinckrodt Pharma 18
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19
Licensing Agreements 21
JCR Pharma Enters into Licensing Agreement with Mesoblast 21
Mesoblast Enters into Licensing Agreement with TiGenix 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 23
Equity Offering 24
Mesoblast Raises USD40 Million in Rights Offering of Shares 24
Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26
Mesoblast Raises USD40 Million in Private Placement of Shares 27
Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28
Mesoblast Raises USD68 Million in Public Offering of ADSs 29
Mesoblast Raises USD44.8 Million in Private Placement of Shares 31
Mesoblast Completes Private Placement Of Shares For US$174 Million 32
Acquisition 33
Teva Pharma Sells Stake in Mesoblast 33
Mesoblast Ltd – Key Competitors 34
Mesoblast Ltd – Key Employees 35
Mesoblast Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 30, 2018: Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights 37
May 31, 2018: Mesoblast Reports Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 44
Feb 27, 2018: Mesoblast Announces Financial Results for the Half-Year Ended December 31, 2017 47
Aug 30, 2017: Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 52
Feb 26, 2017: Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016 58
Corporate Communications 62
Jul 11, 2018: Mesoblast Names Shawn Cline Tomasello As Board Director 62
Jun 19, 2018: Mesoblast Names Joseph R. Swedish As Board Director 63
May 30, 2018: Mesoblast Names Josh Muntner As New Chief Financial Officer 64
Product News 65
10/29/2018: JCR to initiate development of TEMCELL HS Inj. (JR-031EB) for the indication of epidermolysis bullosa 65
Product Approvals 66
Mar 07, 2017: FDA Grants Fast Track Designation For Mesoblast’s Cell Therapy In Children With Acute Graft Versus Host Disease 66
Clinical Trials 67
Sep 20, 2018: Children treated with remestemcel-l continue to have strong survival outcomes at six months in mesoblast’s phase 3 trial for acute graft versus host disease 67
Jun 21, 2018: Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting 68
May 08, 2018: Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting 69
Feb 22, 2018: Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease 70
Dec 20, 2017: Mesoblasts Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment 71
Sep 25, 2017: Mesoblast Presents Update on lead product candidate MSC-100-IV at Global Healthcare Conferences 72
Aug 16, 2017: Positive Trial Results of Mesoblast Cell Therapy in Post-traumatic Osteoarthritis Published in Arthritis Research & Therapy 73
Apr 10, 2017: Successful Interim Analysis of Efficacy Endpoint In Mesoblasts Phase 3 Trial for Chronic Heart Failure 74
Apr 03, 2017: FDA Clears Heart Disease Trial At Harvard’s Boston Children’s Hospital Using Mesoblast’s Cell Therapy In Children With Congenital Heart Disease 75
Mar 31, 2017: Independent Data Monitoring Committee Initiates Process for Interim Analysis of Mesoblasts Phase 3 Chronic Heart Failure Trial 76
Other Significant Developments 77
Dec 07, 2017: Mesoblast Named Global Technology Leader in Cell Therapy Industry 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Mesoblast Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To US$100 Million 12
Mesoblast Raises USD10 Million in Financing 14
Mesoblast Enters into Partnership with Tasly Pharma 16
Mesoblast Enters into Agreement with Cartherics 17
Mesoblast Enters into Agreement with Mallinckrodt Pharma 18
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19
JCR Pharma Enters into Licensing Agreement with Mesoblast 21
Mesoblast Enters into Licensing Agreement with TiGenix 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 23
Mesoblast Raises USD40 Million in Rights Offering of Shares 24
Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26
Mesoblast Raises USD40 Million in Private Placement of Shares 27
Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28
Mesoblast Raises USD68 Million in Public Offering of ADSs 29
Mesoblast Raises USD44.8 Million in Private Placement of Shares 31
Mesoblast Completes Private Placement Of Shares For US$174 Million 32
Teva Pharma Sells Stake in Mesoblast 33
Mesoblast Ltd, Key Competitors 34
Mesoblast Ltd, Key Employees 35
Mesoblast Ltd, Other Locations 36
Mesoblast Ltd, Subsidiaries 36
List of Figures
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10